Reprogramming of B lymphoid cells in human lymphoma pathogenesis

Cell Cycle

Volumn 5, Issue 10, 2006, Pages 1057-1061

  Janz, Martin ^b   Dörken, Bernd ^b   Mathas, Stephan ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b NONE

Author keywords

ABF 1; E2A; Hodgkin; Id2; Lymphoma; Reprogramming

Indexed keywords

HOMODIMER; TRANSCRIPTION FACTOR E2A;

B CELL LYMPHOMA; CANCER GROWTH; CELL DIFFERENTIATION; CELL MATURATION; GENE CONTROL; GENE DISRUPTION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HODGKIN DISEASE; LABORATORY; LYMPHOID CELL; MALIGNANT TRANSFORMATION; NONHUMAN; ONTOGENY; PHENOTYPE; REED STERNBERG CELL; REVIEW;

EID: 33646812256     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.10.2737     Document Type: Review

References (65)

1. Hu M, Krause D, Greaves M, Sharkis S, Dexter M, Heyworth C, Enver T. Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev 1997; 11:774-85.
2. Enver T, Greaves M. Loops, lineage, and leukemia. Cell 1998; 94:9-12.
3. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol 2004; 22:55-79.
4. Singh H, Medina KL, Pongubala JM. Contingent gene regulatory networks and B cell fate specification. Proc Natl Acad Sci USA 2005; 102:4949-53.
5. Bain G, Maandag EC, Izon DJ, Amsen D, Kruisbeek AM, Weintraub BC, Krop I, Schlissel MS, Feeney AJ, van Roon M. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 1994; 79:885-92.
6. Zhuang Y, Soriano P, Weintraub H. The helix-loop-helix gene E2A is required for B cell formation. Cell 1994; 79:875-84.
7. Lin H, Grosschedl R. Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature 1995; 376:263-7.
8. Sigvardsson M. Overlapping expression of early B-cell factor and basic helix-loop-helix proteins as a mechanism to dictate B-lineage-specific activity of the lambda5 promoter. Mol Cell Biol 2000; 20:3640-54.
9. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999; 401:556-62.
10. Urbanek P, Wang ZQ, Fetka I, Wagner EF, Busslinger M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 1994; 79:901-12.
11. Rolink AG, Nutt SL, Melchers F, Busslinger M. Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors. Nature 1999; 401:603-6.
12. Heavey B, Charalambous C, Cobaleda C, Busslinger M. Myeloid lineage switch of Pax5 mutant but not wild-type B cell progenitors by C/EBPalpha and GATA factors. EMBO J 2003; 22:3887-97.
13. Horcher M, Souabni A, Busslinger M. Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity 2001; 14:779-90.
14. Mikkola I, Heavey B, Horcher M, Busslinger M. Reversion of B cell commitment upon loss of Pax5 expression. Science 2002; 297:110-3.
15. Kee BL, Quong MW, Murre C. E2A proteins: Essential regulators at multiple stages of B-cell development. Immunol Rev 2000; 175:138-49.
16. Ikawa T, Kawamoto H, Wright LY, Murre C. Long-term cultured E2A-deficient hematopoietic progenitor cells are pluripotent. Immunity 2004; 20:349-60.
17. Xie H, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into macrophages. Cell 2004; 117:663-76.
18. Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J, MacDonald HR, Aguet M. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999; 10:547-58.
19. Wilson A, MacDonald HR, Radtke F. Notch 1-deficient common lymphoid precursors adopt a B cell fate in the thymus. J Exp Med 2001; 194:1003-12.
20. Pui JC, Allman D, Xu L, DeRocco S, Karnell FG, Bakkour S, Lee JY, Kadesch T, Hardy RR, Aster JC, Pear WS. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999; 11:299-308.
21. Ordentlich P, Lin A, Shen CP, Blaumueller C, Matsuno K, Artavanis-Tsakonas S, Kadesch T. Notch inhibition of E47 supports the existence of a novel signaling pathway. Mol Cell Biol 1998; 18:2230-9.
22. Nie L, Xu M, Vladimirova A, Sun XH. Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J 2003; 22:5780-92.
23. Smith EM, Akerblad P, Kadesch T, Axelson H, Sigvardsson M. Inhibition of EBF function by active Notch signaling reveals a novel regulatory pathway in early B-cell development. Blood 2005; 106:1995-2001.
24. Souabni A, Cobaleda C, Schebesta M, Busslinger M. Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity 2002; 17:781-93.
25. DeKoter RP, Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 2000; 288:1439-41.
26. Shen CP, Kadesch T. B-cell-specific DNA binding by an E47 homodimer. Mol Cell Biol 1995; 15:4518-24.
27. Sawada S, Littman DR. A heterodimer of HEB and an E12-related protein interacts with the CD4 enhancer and regulates its activity in T-cell lines. Mol Cell Biol 1993; 13:5620-8.
28. Barndt RJ, Dai M, Zhuang Y. Functions of E2A-HEB heterodimers in T-cell development revealed by a dominant negative mutation of HEB. Mol Cell Biol 2000; 20:6677-85.
29. Rivera R, Murre C. The regulation and function of the Id proteins in lymphocyte development. Oncogene 2001; 20:8308-16.
30. Heemskerk MH, Blom B, Nolan G, Stegmann AP, Bakker AQ, Weijer K, Res PC, Spits H. Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J Exp Med 1997; 186:1597-602.
31. Sun XH. Constitutive expression of the Id1 gene impairs mouse B cell development. Cell 1994; 79:893-900.
32. Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, Nishikawa S, Gruss P. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999; 397:702-6.
33. Hacker C, Kirsch RD, Ju XS, Hieronymus T, Gust TC, Kuhl C, Jorgas T, Kurz SM, Rose-John S, Yokota Y, Zenke M. Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol 2003; 4:380-6.
34. Laiosa CV, Stadtfeld M, Graf T. Determinants of lymphoid-myeloid lineage diversification. Annu Rev Immunol 2006, (Epub ahead of print).
35. Re D, Küppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 2005; 23:6379-86.
36. Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S, Anagnostopoulos I, Lietz A, Sigvardsson M, Jundt F, Jöhrens K, Bommert K, Stein H, Dörken B. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2006; 7:207-15.
37. Küppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998; 16:471-93.
38. Schwering I, Bräuninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, Hansmann ML, Dalla-Favera R, Rajewsky K, Küppers R. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 101:1505-12.
39. Stein H, Marafioti T, Foss HD, Laumen H, Hummel M, Anagnostopoulos I, Wirth T, Demel G, Falini B. Downregulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001; 97:496-501.
40. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 2002; 21:4908-20.
41. Jundt F, Kley K, Anagnostopoulos I, Schulze Pröbsting K, Greiner A, Mathas S, Scheidereit C, Wirth T, Stein H, Dörken B. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 2002; 99:3060-2.
42. Matthias P, Rolink AG. Transcriptional networks in developing and mature B cells. Nat Rev Immunol 2005; 5:497-508.
43. Ushmorov A, Leithäuser F, Sakk O, Weinhausel A, Popov SW, Möller P, Wirth T. Epigenetic processes play a major role in B-cell-speafic gene silencing in classical Hodgkin lymphoma. Blood 2006; 107:2493-500.
44. Korkolopoulou P, Cordell J, Jones M, Kaklamanis L, Tsenga A, Gatter KC, Mason DY. The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease. Histopathology 1994; 24:511-5.
45. Watanabe K, Yamashita Y, Nakayama A, Hasegawa Y, Kojima H, Nagasawa T, Mori N. Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease. Histopathology 2000; 36:353-61.
46. Massari ME, Rivera RR, Voland JR, Quong MW, Breit TM, van Dongen JJ, de Smit O, Murre C. Characterization of ABF-1, a novel basic helix-loop-helix transcription factor expressed in activated B lymphocytes. Mol Cell Biol 1998; 18:3130-9.
47. Roberts EC, Deed RW, Inoue T, Norton JD, Sharrocks AD. Id helix-loop-helix proteins antagonize pax transcription factor activity by inhibiting DNA binding. Mol Cell Biol 2001; 21:524-33.
48. Lazorchak A, Jones ME, Zhuang Y. New insights into E-protein function in lymphocyte development. Trends Immunol 2005; 26:334-8.
49. Engel I, Murre C. E2A proteins enforce a proliferation checkpoint in developing thymocytes. EMBO J 2004; 23:202-11.
50. Engel I, Murre C. Ectopic expression of E47 or E12 promotes the death of E2A-deficient lymphomas. Proc Natl Acad Sci USA 1999; 96:996-1001.
51. Arguello M, Sgarbanti M, Hernandez E, Mamane Y, Sharma S, Servant M, Lin R, Hiscott J. Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene 2003; 22:964-73.
52. Leithäuser F, Bäuerle M, Huynh MQ, Möller P. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood 2001; 98:2762-70.
53. Ambinder R. Infection and lymphoma. N Engl J Med 2003; 349:1309-11.
54. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998; 9:405-11.
55. Alber G, Kim KM, Weiser P, Riesterer C, Carsetti R, Reth M. Molecular mimicry of the antigen receptor signalling motif by transmembrane proteins of the Epstein-Barr virus and the bovine leukaemia virus. Curr Biol 1993; 3:333-9.
56. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood 2005; 106:4339-44.
57. Höpken UE, Foss HD, Meyer D, Hinz M, Leder K, Stein H, Lipp M. Upregulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 2002; 99:1109-16.
58. Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99:3398-403.
59. Chapman AL, Rickinson AB. Epstein-Barr virus in Hodgkin's disease. Ann Oncol 1998; 9(Suppl 5):S5-16.
60. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186-91.
61. Portis T, Dyck P, Longnecker R. Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 102:4166-78.
62. Mowen KA, Glimcher LH. Signaling pathways in Th2 development. Immunol Rev 2004; 202:203-22.
63. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dörken B. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100:2961-9.
64. Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S, Dörken B, Zenke M, Stein H, Scheidereit C. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196:605-17.
65. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dörken B, Scheidereit C. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002; 21:4104-13.